
Ep. 695 Optimizing Personalized Dosimetry for Y90 Radioembolization with Dr. Russell Reeves and Dr. Shamar Young
Y90 radioembolization is not a TACE-like procedure. “It's just not. It is a radiation procedure,” says Dr. Shamar Young, and that means the dose each tumor receives, including the dose reaching its coldest 5% (D95), drives both outcomes and side effects. On this episode of the BackTable Podcast, interventional radiologist Dr. Kavi Krishnasamy talks with Dr. Young, interventional radiologist at the University of Arizona and CEO of TeleDaaS, and Dr. Russell Reeves, the only interventional radiologist at Samaritan Medical Center in upstate New York, about what personalized dosimetry really means in 2026, from D95, V400, and dose-volume histograms to single-compartment, partition, and voxel-based methods, lung shunt estimates with planar imaging versus SPECT/CT, and the value of post-treatment dosimetry. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by TeleDaaS https://www.teledaas.com/ --- Timestamps 00:00 - Introduction 02:17 - Choosing Liver-Directed Therapy 08:05 - Bringing Advanced Dosimetry to Community Practice 09:36 - D95, V400, and Defining Personalized Dosimetry 24:57 - Dosimetry Without Software 29:02 - Mapping, Lung Shunt, and Post-Treatment Dosimetry 40:38 - Single-Session Y90 42:50 - Coding and Documentation for Dosimetry 48:59 - Who Should Do the Dosimetry? 58:26 - Setting Up Outsourced Dosimetry 1:01:55 - Why Interventional Radiologists Struggle to Outsource 1:10:37 - Cases: Large HCC and Metastatic Breast Cancer 1:26:45 - Closing Remarks --- More about this episode Running a Y90 program with advanced dosimetry is possible even for a solo interventional radiologist two years out of training, and Dr. Russell Reeves describes how he does it at a 220-bed community hospital. The three physicians compare in-house software, radiation oncology, core labs, and outsourced dosimetry as a service, explain how to document dosimetry so it is coded correctly, and discuss why interventional radiologists have been slow to outsource. Dr. Reeves closes with two cases, a large hepatocellular carcinoma with tumor in the vein and metastatic breast cancer after prior liver SBRT, that show how dose planning sets the limits of treatment. --- Resources Berman ZT, et al. Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma. Radiology. 2026 https://doi.org/10.1148/radiol.251923 Pianka KT, et al. Comparison of Dosimetry Models and Dose Thresholds for Predicting Pathologic Response to Yttrium-90 Radioembolization with Glass Microspheres. Cardiovasc Intervent Radiol. 2025 https://doi.org/10.1007/s00270-025-04161-0 Salem R, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021 https://doi.org/10.1002/hep.31819 Garin E, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01). Lancet Gastroenterol Hepatol. 2021 https://doi.org/10.1016/S2468-1253(20)30290-9 Young S, et al. Lung shunt fraction calculations before Y-90 transarterial radioembolization: Comparison of accuracy and clinical significance of planar scintigraphy and SPECT/CT. Diagn Interv Imaging. 2023 https://doi.org/10.1016/j.diii.2022.12.002 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app


















